Sökning: onr:"swepub:oai:DiVA.org:liu-122778" > N-terminal pro-B-ty...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04967naa a2200505 4500 | |
001 | oai:DiVA.org:liu-122778 | |
003 | SwePub | |
008 | 151123s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1227782 URI |
024 | 7 | a https://doi.org/10.1097/ALN.00000000000007282 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Potgieter, Danielleu University of KwaZulu Natal, South Africa4 aut |
245 | 1 0 | a N-terminal pro-B-type Natriuretic Peptides Prognostic Utility Is Overestimated in Meta-analyses Using Study-specific Optimal Diagnostic Thresholds |
264 | 1 | b LIPPINCOTT WILLIAMS and WILKINS,c 2015 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies|CLS Behring Biotherapies for Life (Vienna, Austria); Astra Zeneca (Vienna, Austria); Boehringer Ingelheim (Ingelheim, Germany); CLS Behring Biotherapies for Life; Novo Nordisk Pharma GmbH (Vienna, Austria) | |
520 | a Background:N-terminal fragment B-type natriuretic peptide (NT-proBNP) prognostic utility is commonly determined post hoc by identifying a single optimal discrimination threshold tailored to the individual study population. The authors aimed to determine how using these study-specific post hoc thresholds impacts meta-analysis results. Methods: The authors conducted a systematic review of studies reporting the ability of preoperative NT-proBNP measurements to predict the composite outcome of all-cause mortality and nonfatal myocardial infarction at 30 days after noncardiac surgery. Individual patient-level data NT-proBNP thresholds were determined using two different methodologies. First, a single combined NT-proBNP threshold was determined for the entire cohort of patients, and a meta-analysis conducted using this single threshold. Second, study-specific thresholds were determined for each individual study, with meta-analysis being conducted using these study-specific thresholds. Results: The authors obtained individual patient data from 14 studies (n = 2,196). Using a single NT-proBNP cohort threshold, the odds ratio (OR) associated with an increased NT-proBNP measurement was 3.43 (95% CI, 2.08 to 5.64). Using individual study-specific thresholds, the OR associated with an increased NT-proBNP measurement was 6.45 (95% CI, 3.98 to 10.46). In smaller studies (less than100 patients) a single cohort threshold was associated with an OR of 5.4 (95% CI, 2.27 to 12.84) as compared with an OR of 14.38 (95% CI, 6.08 to 34.01) for study-specific thresholds. Conclusions:Post hoc identification of study-specific prognostic biomarker thresholds artificially maximizes biomarker predictive power, resulting in an amplification or overestimation during meta-analysis of these results. This effect is accentuated in small studies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
700 | 1 | a Simmers, Daleu University of KwaZulu Natal, South Africa4 aut |
700 | 1 | a Ryan, Lisau Greys Hospital, South Africa4 aut |
700 | 1 | a Biccard, Bruce M.u University of KwaZulu Natal, South Africa4 aut |
700 | 1 | a Lurati-Buse, Giovanna A.u University of Basel Hospital, Switzerland4 aut |
700 | 1 | a Cardinale, Daniela M.u European Institute Oncol, Italy4 aut |
700 | 1 | a Chong, Carol P. W.u Northern Hospital, Australia; University of Melbourne, Australia4 aut |
700 | 1 | a Cnotliwy, Miloslawu Pomeranian Medical University, Poland4 aut |
700 | 1 | a Farzi, Sylvia I.u Medical University of Graz, Austria4 aut |
700 | 1 | a Jankovic, Radmilo J.u University of Nis, Serbia4 aut |
700 | 1 | a Kwang Lim, Wenu Medical University of Graz, Austria4 aut |
700 | 1 | a Mahla, Elisabethu Medical University of Graz, Austria4 aut |
700 | 1 | a Manikandan, Ramaswamyu Stepping Hill Hospital, England4 aut |
700 | 1 | a Oscarsson, Annau Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)annos67 |
700 | 1 | a Phy, Michael P.u Texas Technical University, TX 79430 USA4 aut |
700 | 1 | a Rajagopalan, Sriramu University of Aberdeen, Scotland; Aberdeen Royal Infirm, Scotland4 aut |
700 | 1 | a Van Gaal, William J.u University of Melbourne, Australia4 aut |
700 | 1 | a Waliszek, Mareku M Pirogow Prov Specialist Hospital, Poland4 aut |
700 | 1 | a Rodseth, Reitze N.u University of KwaZulu Natal, South Africa; Cleveland Clin, OH 44106 USA4 aut |
710 | 2 | a University of KwaZulu Natal, South Africab Greys Hospital, South Africa4 org |
773 | 0 | t Anesthesiologyd : LIPPINCOTT WILLIAMS and WILKINSg 123:2, s. 264-271q 123:2<264-271x 0003-3022x 1528-1175 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-122778 |
856 | 4 8 | u https://doi.org/10.1097/ALN.0000000000000728 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy